PRPF19 promotes tongue cancer growth and chemoradiotherapy resistance

Yihong He; Changhao Huang; Kaimei Cai; Pei Liu; Xueyan Chen; Y I Xu; Zhengnan Ming; Qingqing Liu; Qiongxuan Xie; Xue Xia; Yangqing Sun; Junli Luo; Rui Wei

doi:10.1093/abbs/gmab059

PRPF19 promotes tongue cancer growth and chemoradiotherapy resistance

Acta Biochim Biophys Sin (Shanghai). 2021 Jul 5;53(7):893-902. doi: 10.1093/abbs/gmab059.

Authors

Yihong He^{1

2}, Changhao Huang¹, Kaimei Cai¹, Pei Liu², Xueyan Chen^{1

2}, Y I Xu¹, Zhengnan Ming^{1

3}, Qingqing Liu^{1

2}, Qiongxuan Xie², Xue Xia^{1

3}, Yangqing Sun^{1

2}, Junli Luo¹, Rui Wei²

Affiliations

¹ Department of General Surgery and the Hunan Provincial Key Lab of Precision Diagnosis and Treatment for Gastrointestinal Tumor, Xiangya Hospital, Central South University, Changsha 410008, China.
² Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, China.
³ Department of Biochemistry and Molecular Biology, School of Life Sciences, Central South University, Changsha 410008, China.

PMID: 33954334
DOI: 10.1093/abbs/gmab059

Abstract

Pre-mRNA processing factor 19 (PRPF19) is a multifaceted protein and participates in DNA damage response and pre-mRNA processing. The role of PRPF19 in cancer is unclear. Here, we report that the expression of PRPF19 in human tongue cancer is associated with unfavorable prognosis. Overexpression of PRPF19 promotes while knockdown of PRPF19 inhibits tongue cancer cell migration, proliferation, and tumor growth. Overexpression of PRPF19 increases the resistance of tongue cancer cells to radiation and cisplatin treatment. Furthermore, PRPF19 regulates the expression of solute carrier family 40 member 1 (SLC40A1) and mono-ADP ribosylhydrolase 2 (MACROD2), knockdown of SLC40A1 or MACROD2 decreases the sensitivity of tongue cancer cells to radiation and cisplatin treatment. Thus, our results establish a key role of PRPF19 in tongue cancer growth and chemoradiotherapy resistance, targeting PRPF19 would be an effective therapeutic strategy for tongue cancer, especially for those resistant to chemoradiotherapy.

Keywords: PRPF19; chemoradiotherapy resistance; recurrence; tongue cancer.

© The Author(s) 2021. Published by Oxford University Press on behalf of the Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

MeSH terms

Animals
Cell Line, Tumor
Cell Movement* / drug effects
Cell Movement* / radiation effects
Cell Proliferation* / drug effects
Cell Proliferation* / radiation effects
Chemoradiotherapy*
Cisplatin / pharmacology*
DNA Repair Enzymes / genetics
DNA Repair Enzymes / metabolism*
Drug Resistance, Neoplasm* / drug effects
Drug Resistance, Neoplasm* / radiation effects
Female
Humans
Male
Mice
Mice, Inbred NOD
Mice, SCID
Middle Aged
Neoplasm Proteins / genetics
Neoplasm Proteins / metabolism
Nuclear Proteins / genetics
Nuclear Proteins / metabolism*
RNA Splicing Factors / genetics
RNA Splicing Factors / metabolism*
Radiation Tolerance* / drug effects
Radiation Tolerance* / radiation effects
Radiation, Ionizing
Tongue Neoplasms* / genetics
Tongue Neoplasms* / metabolism
Tongue Neoplasms* / pathology
Tongue Neoplasms* / therapy
Xenograft Model Antitumor Assays

Substances

Neoplasm Proteins
Nuclear Proteins
RNA Splicing Factors
DNA Repair Enzymes
PRPF19 protein, human
Cisplatin

Abstract

MeSH terms

Substances

Grants and funding